Human cytomegalovirus, endothelial function and atherosclerosis

Herpes

Volumn 12, Issue 2, 2005, Pages 42-45

  Grahame Clarke, Cairistine ^a  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Atherosclerosis; Endothelial function; Human cytomegalovirus; Marek's disease virus; Pre eclampsia; Transplant arterial disease

Indexed keywords

ACETYLCHOLINE; BRADYKININ; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCERYL TRINITRATE; HLA G ANTIGEN; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE;

ARTERY DISEASE; ATHEROSCLEROSIS; AVIAN LYMPHOMATOSIS HERPETOVIRUS; CYTOMEGALOVIRUS INFECTION; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; OXIDATIVE STRESS; PREECLAMPSIA; PRIORITY JOURNAL; REVIEW; SEROLOGY; SHEAR STRESS; TRANSPLANTATION; VASCULAR ENDOTHELIUM; VASODILATATION; VIRUS REPLICATION;

ATHEROSCLEROSIS; CYTOMEGALOVIRUS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; NITRIC OXIDE; PRE-ECLAMPSIA; PREGNANCY; TRANSPLANTATION;

CYTOMEGALOVIRUS; GALLID HERPESVIRUS 2; HUMAN HERPESVIRUS 5; MARDIVIRUS;

EID: 27244453285     PISSN: 09697667     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-952.
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-809.
3. Bruggeman CA. Does cytomegalovirus play a role in atherosclerosis? Herpes 2000;7:51-54.
4. Reinhardt B, Minisini R, Mertens T. Opinion article: cytomegalovirus is a risk factor in atherogenesis. Herpes 2002;9:21-23.
5. Eerdmans PH, Persoons MC, Debets SJ, Struijker Boudier HA, Smits JF, Bruggeman CA et al. Impaired arterial reactivity following cytomegalovirus infection in the immunosuppressed rat. Br J Pharmacol 1996;119:637-646.
6. Burnett MS, Durrani S, Stabile E, Saji M, Lee CW, Kinnaird TD et al. Murine cytomegalovirus infection increases aortic expression of proatherosclerotic genes. Circulation 2004;109:893-897.
7. Vliegen I, Duijvestijn A, Grauls G, Herngreen S, Bruggeman C, Stassen F. Cytomegalovirus infection aggravates atherogenesis in apoE knockout mice by both local and systemic immune activation. Microbes Infect 2004;6:17-24.
8. Rott D, Zhu J, Zhou YF, Burnett MS, Zalles-Ganley A, Epstein SE. IL-6 is produced by splenocytes derived from CMV-infected mice in response to CMV antigens, and induces MCP-1 production by endothelial cells: a new mechanistic paradigm for infection-induced atherogenesis. Atherosclerosis 2003;170:223-228.
9. Muhlestein JB, Anderson JL. Infectious serology and atherosclerosis: how burdensome is the risk? Circulation 2003;107:220-222.
10. Epstein SE. The multiple mechanisms by which infection may contribute to atherosclerosis development and course. Circ Res 2002;90:2-4.
11. Nieto FJ. Viruses and atherosclerosis: a critical review of the epidemiologic evidence. Am Heart J 1999;138:S453-S460.
12. Ridker PM, Hennekens CH, Stampfer MJ, Wang F. Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. Circulation 1998;98:2796-2799.
13. Haider AW, Wilson PW, Larson MG, Evans JC, Michelson EL, Wolf PA et al. The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: a prospective study. J Am Coll Cardiol 2002;40:1408-1413.
14. Danesh J. Coronary heart disease, Helicobacter pylori, dental disease, Chlamydia pneumoniae, and cytomegalovirus: meta-analyses of prospective studies. Am Heart J 1999;138:S434-S437.
15. Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Rippin G et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation 2002;105:15-21.
16. Rupprecht HJ, Blankenberg S, Bickel C, Rippin G, Hafner G, Prellwitz W et al. Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation 2001;104:25-31.
17. Zhu J, Quyyumi AA, Norman JE, Csako G, Waclawiw MA, Shearer GM et al. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am J Cardiol 2000;85:140-146.
18. Prasad A, Zhu J, Halcox JP, Waclawiw MA, Epstein SE, Quyyumi AA. Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation 2002;106:184-190.
19. Smieja M, Gnarpe J, Lonn E, Gnarpe H, Olsson G, Yi Q et al. Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003;107:251-257.
20. Muhlestein JB, Horne BD, Carlquist JF, Madsen TE, Bair TL, Pearson RR et al. Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation 2000;102:1917-1923.
21. Blankenberg S, Rupprecht HJ, Bickel C, Espinola-Klein C, Rippin G, Hafner G et al. Cytomegalovirus infection with interleukin-6 response predicts cardiac mortality in patients with coronary artery disease. Circulation 2001;103:2915-2921.
22. Danesh J, Collins R, Peto R. Chronic infections and coronary artery disease: is there a link? Lancet 1997;350:430-436.
23. Rothenbacher D, Brenner H, Hoffmeister A, Mertens T, Persson K, Koenig W. Relationship between infectious burden, systemic inflammatory response, and risk of stable coronary artery disease: role of confounding and reference group. Atherosclerosis 2003;170:339-345.
24. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethyl-arginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004;24:1023-1030.
25. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-265.
26. Vallance P, Chan N. Endothelial function and nitric oxide: clinical relevance. Heart 2001;85:342-350.
27. Calver A, Collier J, Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 1992;90:2548-2554.
28. Benjamin EJ, Larson MG, Keyes MJ, Mitchell GF, Vasan RS, Keaney JF et al. Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study. Circulation 2004;109:613-619.
29. Kuvin JT, Karas RH. Clinical utility of endothelial function testing: ready for prime time? Circulation 2003;107:3243-3247.
30. Grahame-Clarke C, Chan NN, Andrew D, Ridgway GL, Betteridge DJ, Emery V et al. Human cytomegalovirus seropositivity is associated with impaired vascular function. Circulation 2003;108:678-683.
31. Khairy P, Rinfret S, Tardif JC, Marchand R, Shapiro S, Brophy J et al. Absence of association between infectious agents and endothelial function in healthy young men. Circulation 2003;107:1966-1971.
32. Potena L, Grigioni F, Ortolani P, Magnani G, Marrozzini C, Falchetti E et al. Relevance of cytomegalovirus infection and coronary-artery remodeling in the first year after heart transplantation: a prospective three-dimensional intravascular ultrasound study. Transplantation 2003;75:839-843.
33. Valantine HA. Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant "atheroma". Transplantation 2003;76:891-899.
34. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989;261:3561-3566.
35. Fateh-Moghadam S, Bocksch W, Wessely R, Jager G, Hetzer R, Gawaz M. Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy. Transplantation 2003;76:1470-1474.
36. Wechsler ME, Giardina EG, Sciacca RR, Rose EA, Barr ML. Increased early mortality in women undergoing cardiac transplantation. Circulation 1995;91:1029-1035.
37. Valantine HA, Gao SZ, Menon SG, Renlund DG, Hunt SA, Oyer P et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 1999;100:61-66.
38. Koskinen PK, Kallio EA, Tikkanen JM, Sihvola RK, Hayry PJ, Lemstrom KB. Cytomegalovirus infection and cardiac allograft vasculopathy. Transpl Infect Dis 1999;1:115-126.
39. Gulizia JM, Kandolf R, Kendall TJ, Thieszen SL, Wilson JE, Radio SJ et al. Infrequency of cytomegalovirus genome in coronary arteriopathy of human heart allografts. Am J Pathol 1995;147:461-475.
40. Sambiase NV, Higuchi ML, Nuovo G, Gutierrez PS, Fiorelli AI, Uip DE et al. CMV and transplant-related coronary atherosclerosis: an immunohistochemical, in situ hybridization, and polymerase chain reaction in situ study. Mod Pathol 2000;13:173-179.
41. Petrakopoulou P, Kubrich M, Pehlivanli S, Meiser B, Reichart B, von Scheldt W et al. Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function. Circulation 2004;110 (Suppl 1):II207-II212.
42. Weis M, Kledal TN, Lin KY, Panchal SN, Gao SZ, Valantine HA et al. Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis. Circulation 2004;109:500-505.
43. Hannaford P, Ferry S, Hirsch S. Cardiovascular sequelae of toxaemia of pregnancy. Heart 1997;77:154-158.
44. Chesley LC. Remote prognosis after eclampsia. Perspect Nephrol Hypertens 1976;5:31-40.
45. Chesley LC. Hypertension in pregnancy: definitions, familial factor, and remote prognosis. Kidney Int 1980;18:234-240.
46. Jonsdottir LS, Arngrimsson R, Geirsson RT, Sigvaldason H, Sigfusson N. Death rates from ischemic heart disease in women with a history of hypertension in pregnancy. Acta Obstet Gynecol Scand 1995;74:772-776.
47. Agatisa PK, Ness RB, Roberts JM, Costantino JP, Kuller LH, McLaughlin MK. Impairment of endothelial function in women with a history of preeclampsia: an indicator of cardiovascular risk. Am J Physiol Heart Circ Physiol 2004;286:H1389-H1393.
48. Yamamoto-Tabata T, McDonagh S, Chang HT, Fisher S, Pereira L. Human cytomegalovirus interleukin-10 downregulates metalloproteinase activity and impairs endothelial cell migration and placental cytotrophoblast invasiveness in vitro. J Virol 2004;78:2831-2840.
49. Szmitko PE, Wang CH, Weisel RD, Jeffries GA, Anderson TJ, Verma S. Biomarkers of vascular disease linking inflammation to endothelial activation: Part II. Circulation 2003;108:2041-2048.
50. Pizzato N, Garmy-Susini B, Le Bouteiller P, Lenfant F. Down-regulation of HLA-G1 cell surface expression in human cytomegalovirus infected cells. Am J Reprod 2003;50:328-333.
51. Carreiras M, Montagnani S, Layrisse Z. Preeclampsia: a multifactorial disease resulting from the interaction of the fetomaternal HLA genotype and HCMV infection. Am J Reprod Immunol 2002;48:176-183.
52. Holden DP, Fickling SA, Whitley GS, Nussey SS. Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia. Am J Obstet Gynecol 1998;178:551-556.
53. Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolaides KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 2003;361:1511-1517.
54. von Dadelszen P, Magee LA, Krajden M, Alasaly K, Popovska V, Devarakonda RM et al. Levels of antibodies against cytomegalovirus and Chlamydophila pneumoniae are increased in early onset preeclampsia. BJOG 2003;110:725-730.
55. Fabricant CG, Fabricant J. Atherosclerosis induced by infection with Marek's disease herpesvirus in chickens. Am Heart J 1999;138:S465-S468.
56. Jarosinski KW, Tunis R, O'Connell PH, Markowski-Grimsrud CJ, Schat KA. Influence of genetic resistance of the chicken and virulence of Marek's disease virus (MDV) on nitric oxide responses after MDV infection. Avion Dis 2002;46:636-649.